Samsung Bioepis Gets FDA Approval for Biosimilar to AstraZeneca’s Soliris

The South Korean company’s Epysqli is now FDA-approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in the U.S., having grabbed the lead in the Soliris biosimilar market in Europe.